Comprehensive Assessment of Candidate Genes and Serological Markers for the Detection of Prostate Cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 12, Issue 12, 2003, Pages 1429-1437

  Nam, Robert K ^a,d   Zhang, William W ^b   Trachtenberg, John ^b   Jewett, Michael A S ^b   Emami, Marjan ^a   Vesprini, Danny ^b   Chu, William ^b   Ho, Minnie ^b   Sweet, Joan ^b   Evans, Andrew ^b   Toi, Ants ^b   Pollak, Michael ^c   Narod, Steven A ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYTOCHROME P450 17; CYTOCHROME P450 3A4; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; VITAMIN D RECEPTOR;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; GST M1 GENE; GST P1 GENE; GST T1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RECEPTOR GENE; RISK ASSESSMENT; SEROCONVERSION; SRD5A2 GENE;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BIOPSY, NEEDLE; COHORT STUDIES; DNA, NEOPLASM; GENE FREQUENCY; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 9144263792     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Potosky, A. L., Miller, B. A., Albertsen, P. C., and Kramer, B. S. The role of increasing detection in the rising incidence of prostate cancer. J. Am. Med. Assoc., 273: 548-552, 1995.
2. Canadian Cancer Statistics 2000. Toronto: National Cancer Institute of Canada, 2000.
3. Stamey, T. A., Yang, N., Hay, R., McNeal, J. E., Freiha, F. S., and Redwine, E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Eng. J. Med., 317: 909-915, 1987.
4. Vanchieri, C. Prostate cancer screening trials. Fending off critics to recruit men. J. Natl. Cancer Inst. (Bethesda), 90: 10-12, 1998.
5. Schroder, F. H., and Bangma, C. H. The European randomized study of screening for prostate cancer (ERSPC). Br. J. Urol., 79: 68-71, 1997.
6. Gann, P. H., Hennekens, C. H., and Stampfer, M. J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. J. Am. Med. Assoc., 273: 289-294, 1995.
7. Catalona, W. J., Smith, D. S., Ratiff, T. L., and Basler, J. W. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. J. Am. Med. Assoc., 270: 948-954, 1993.
8. Oesterling, J. E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 145: 907-923, 1991.
9. Catalona, W. J., Southwick, P. C., Slawin, K. M., Partin, A. W., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., Walsh, P. C., Scardino, P. T., Lange, P. H., Gasior, G. H., Loveland, K. G., and Bray, K. R. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology, 56: 255-260, 2000.
10. Gann, P. H., Hennekens, C. H., Ma, J., Longcope, C., and Stampfer, M. J. Prospective study of sex hormone levels and risk of prostate cancer. J. Natl. Cancer Inst. (Bethesda), 88: 1118-1126, 1996.
11. Giovannucci, E., Stampfer, M. J., Krithivas, K., Brown, M., Brufsky, A., Talcott, J., Hennekens, C. H., and Kantoff, P. W. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. USA, 94: 3320-3323, 1997.
12. Ingles, S. A., Ross, R. K., Yu, M. C., Irvine, R. A., La Pera, G., Haile, R. W., and Coetzee, G. A. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst. (Bethesda), 89: 166-170, 1997.
13. Correa-Cerro, L., Berthon, P., Haussler, J., Bochum, S., Drelon, E., Mangin, P., Fournier, G., Paiss, T., Cussenot, O., and Vogel, W. Vitamin D receptor polymorphisms as markers in prostate cancer. Hum. Genet., 105: 281-287, 1999.
14. Makridakis, N., Ross, R. K., Pike, M. C., Chang, L., Stanczyk, F. Z., Kolonel, L. N., Shi, C. Y., Yu, M. C., Henderson, B. E., and Reichardt, J. K. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res., 57: 1020-1022, 1997.
15. Nam, R. K., Toi, A., Vesprini, D., Ho, M., Chu, W., Harvie, S., Sweet, J., Trachtenberg, J., Jewett, M. A. S., and Narod, S. A. The V89L polymorphism of the SRD5A2 gene predicts prostate cancer presence and progression. Urology, 57: 199-204, 2000.
16. Lewis, D. F. V., and Lee-Robichaud, P. Molecular modelling of steroidogenic cytochromes P450 from families CYP11, CYP17, CYP19 and CYP21 based on the CYP102 crystal structure. J. Steroid Biochem. Mol. Biol., 66: 217-233, 1998.
17. Rebbeck, T. R., Jaffe, J. M., Walker, A. H., Wein, A. J., and Malkowicz, S. B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. (Bethesda), 90: 1225-1229, 1998.
18. Edwards, A., Hammond, H. A., Jin, L., Caskey, C. T., and Chakraborty, R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics, 12: 241-253, 1992.
19. Nam, R. K., Elhaji, Y., Krahn, M. D., Hakimi, J., Ho, M., Chu, W., Sweet, J., Trachtenberg, J., Jewett, M. A. S., and Narod, S. A. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J. Urol., 164: 567-572, 2000.
20. Bjelfman, C., Soderstrom, T. G., Brekkan, E., Norlen, B. J., Egevad, L., Unge, T., Andersson, S., and Rane, A. Differential gene expression of steroid 5α-reductase-2 in core needle biopsies from malignant and benign prostatic tissue. J. Clin. Endocr. Metab., 82: 2210-2214, 1997.
21. Morissette, J., Durocher, F., Leblanc, J. F., Normand, T., Labrie, F., and Simard, J. Genetic linkage mapping of the human steroid 5 α-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23→p22. Cytogenet. Cell Genet., 73: 304-307, 1996.
22. Gsur, A., Bernhofer, G., Hinteregger, S., Haidinger, G., Schatzl, G., Madersbacher, S., Marberger, M., Vutuc, C., and Micksche, M. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int. J. Cancer, 87: 434-437, 2000.
23. Halman, C. A., Stampfer, M. J., Giovannucci, E., Ma, J., Decalo, N. E., Kantoff, P. W., and Hunter, D. J. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol. Biomark. Prev., 10: 743-748, 2001.
24. Paris, P. L., Kupelian, P. A., Hall, J. M., Williams, T. L., Levin, H., Klein, E. A., Casey, G., and Witte, J. S. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol. Biomark. Prev., 8: 901-905, 1999.
25. Morrison, N. A., Qi, J. C., Tokita, A., Kelly, P. J., Crofts, L., Nguyen, T. V., Sambrook, P. N., and Elsman, J. A. Prediction of bone density from vitamin D receptor alleles. Nature (Lond.), 367: 284-287, 1994.
26. Hanchette, C. L., and Schwartz, G. G. Geographic patterns of prostate cancer mortality. Cancer (Phila.), 70: 2861-2869, 1992.
27. Chokkalingam, A. P., McGlynn, K. A., Gao, Y. T., Pollak, M., Deng, J., Sesterhenn, I. A., Mostofi, F. K., Fraumeni, J. F., Jr., and Hsing, A. W. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. Cancer Res., 61: 4333-4336, 2001.
28. Xue, W., Irvine, R. A., Yu, M. C., Ross, R. K., Coetzee, G. A., and Ingles, S. A. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res., 60: 839-841, 2000.
29. Xu, J., Meyers, D. A., Sterling, D. A., Zheng, S. L., Catalona, W. J., Cramer, S. D., Bleecker, E. R., and Ohar, J. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. Cancer Epidemiol. Biomark. Prev., 11: 664-669, 2002.
30. Medeiros, R., Morais, A., Vasconcelos, A., Costa, S., Pinto, D., Oliveira, J., Carvalho, R., and Lopes, C. Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate, 53: 88-94, 2002.
31. Rebbeck, T. R. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol. Biomark. Prev., 6: 733-743, 1997.
32. Harries, L. W., Stubbins, M. J., Forman, D., Howard, G. C., and Wolf, C. R. Identification of genetic polymorphisms at the glutathione S-transferase π locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis (Lond.), 18: 641-644, 1997.
33. Seidegard, J., Pero, R. W., Miller, D. G., and Beattie, E. J. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis (Lond.), 7: 751-753, 1986.
34. Katoh, T., Nagata, N., Kuroda, Y., Itoh, H., Kawahara, A., Kuroki, N., Ookuma, R., and Bell, D. A. Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. Carcinogenesis (Lond.), 17: 1855-1859, 1996.
35. Rebbeck, T. R., Walker, A. H., Phelan, C. M., Godwin, A. K., Buetow, K. H., Garber, J. E., Narod, S. A., and Weber, B. L. Defining etiologic heterogeneity in breast cancer using genetic biomarkers. Prog. Clin. Biol. Res., 396: 53-61, 1997.
36. Rebbeck, T. R., Walker, A. H., Jaffe, J. M., White, D. I., Wein, A. J., and Malkowicz, S. B. Glutathione S-transferase-μ (GSTM1) and θ (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol. Biomark. Prev., 8: 283-287, 1999.
37. Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., and Pollak, M. Circulating insulin-like growth factor I and prostate cancer risk: a prospecfive study. Science (Wash. DC), 279: 563-566, 1998.
38. Chokkalingam, A. P., Pollak, M., Fillmore, C-M., Gao, Y-T., Stanczyk, F. Z., Deng, J., Sesterhenn, I. A., Mostofi, F. K., Fears, T. R., Madigan, M. P., Ziegler, R. G., Fraumeni, J. F., and Hsing, A. W. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol. Biomark. Prev., 10: 421-427, 2001.
39. Jernstrom, H., Deal, C., Wilkin, F., Chu, W., Tao, Y., Majeed, N., Hudson, T., Narod, S. A., and Pollak, M. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol. Biomark. Prev., 10: 377-384, 2001.
40. Allen. N. E., Davey, G. K., Key, T. J., Zhang, S., and Narod, S. A. Serum insulin-like growth factor 1 (IGF-1) concentration in men is not associated with the cytosine-adenosine repeat polymorphism of the IGF-1 gene. Cancer Epidemiol. Biomark. Prev., 11: 319-320, 2002.
41. Rosen, C. J., Kurland, E. S., Vereault, D., Adler, R. A., Rackoff, P. J., Craig, W. Y., Witte, S., Rogers, J., and Bilezikian, J. P. Association between serum insulin growth factor-1 (IGF-1) and a simple sequence repeat in IGF-1 gene: implications for genetic studies of bone mineral density. J. Clin. Endocrinol. Metab., 83: 2287-2290, 1998.
42. Barry, M. J., Fowler, F. J. J., O'Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., and Cockett, A. T. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J. Urol., 148: 1549-1557, 1992.
43. Gleason, D. F., and Mellinger, G. T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol., 111: 58-64, 1974.
44. Keetch, D. W., Catalona, W. J., and Smith, D. S. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J. Urol., 151: 1571-1574, 1994.
45. Djavan, B., Ravery, V., Zlotta, A., Dobronski, P., Dobrovits, M., Fakhari, M., Seitz, C., Susani, M., Borkowski, A., Boccon-Gibod, L., Schulman, C. C., and Marberger, M. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: When should we stop? J. Urol., 166: 1679-1683, 2001.
46. Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., deKemion, J. B., Walsh, P. C., Scardino, P. T., Lange, P. H., Subong, E. N. P., Parson, R. E., Gasior, G. H., Loveland, K. G., and Southwick, P. C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. J. Am. Med. Assoc., 279: 1542-1547, 1998.
47. Rietbergen, J. B., Kruger, A. E., Hoedemaeker, R. F., Bangma, C. H., Kirkels, W. J., and Schroder, F. H. Repeat screening for prostate cancer after 1-year follow-up in 984 biopsied men: clinical and pathological features of detected cancer. J. Urol., 160: 2121-2125, 1998.
48. Durkan, G. C., and Greene, D. R. Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? BJU Int., 83: 424-428, 1999.
49. Hayek, O. R., Noble, C. B., de la Taille, A., Bagiella, E., and Benson, M. C. The necessity of a second prostate biopsy cannot be predicted by PSA or PSA derivatives (density or free:total ratio) in men with prior negative prostatic biopsies. Curr. Opin. Urol., 9: 371-375, 1999.
50. Roehl, K. A., Antenor, J. A., and Catalona, W. J. Serial biopsy results in prostate cancer screening study. J. Urol., 167: 2435-2439, 2002.
51. Nam, R. K., Zhang, W. W., Trachtenberg, J., Diamandis, E. P., Toi, A., Emami, M., Ho, M., Tsihlias, J., Sweet, J., Evans, A., Jewett, M. A. S., and Narod, S. A. A single nucleotide polymorphism of the human kallikrein-2 gene (KLK2) highly correlates with serum HK2 levels and their combination significantly enhances prostate cancer detection. J. Clin. Oncol., 21: 2312-2319, 2003.
52. Reichardt, J. K., Makridakis, N., Henderson, B. E., Yu, M. C., Pike, M. C., and Ross, R. K. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res., 55: 3973-3975, 1995.
53. Makridakis, N. M., Ross, R. K., Pike, M. C., Crocitto, L. E., Kolonel, L. N., Pearce, C. L., Henderson, B. E., and Reichardt, J. K. V. Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet, 354: 975-978, 1999.
54. Chan, J. M., Stampfer, M. J., Ma, J., Gann, P., Gaziano, J. M., Pollak, M., and Giovannucci, E. Insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J. Natl. Cancer Inst. (Bethesda), 94: 1099-106, 2002.
55. Harman, S. M., Metter, E. J., Blackman, M. R., Landis, P. K., and Carter. H. B. Serum levels of insulin-like growth factor 1 (IGF-1), IGF-2, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J. Clin. Endocrinol. Metab., 85: 4258-4265, 2000.
56. Stattin, P., Bylund, A., Rinaldi, S., Biessy, C., Dechaud, H., Stenman, U-H., Egevad, L., Riboli, E., Hallmans, G., and Kaaks, R. Plasma insulin-like growth factor-1, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J. Natl. Cancer Inst. (Bethesda), 92: 1910-1917, 2000.
57. Hsing, A. H., Chua, S., Jr., Gao, Y-T., Gentzchein, E., Chang, L., Deng, J., and Stanczyk, F. Z. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J. Natl. Cancer Inst. (Bethesda), 93: 783-789, 2001.
58. Hsing, A. Y., Kadomatsu, K., Bonham, M. J., and Danielpour, D. Regulation of apoptosis induced by transforming growth factor-B1 in nontumorigenic and tumorigenic rat prostatic epithelial cell lines. Cancer Res., 56: 5146-5149, 1996.
59. Baker, J., Hardy, M. P., Zhou, J., Bondy, C., Lupu, F., Bellve, A. R., and Efstratiadis, A. Effects of Igf1 gene null mutation on mouse reproduction. Mol. Endocrinol., 10: 903-918, 1996.
60. Wolk, A., Andersson, S-O., Mantzoros, C. S., Trichopoulos, D., and Adami, H-O. Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate cancer screening? Lancet, 356: 1902-1903, 2000.